Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Biocartis Group NV's Revenue for the
six
months ended in Jun. 2023 was €29.49 Mil. Biocartis Group NV's average Accounts Receivable for the
six
months ended in Jun. 2023 was €19.01 Mil.
Hence, Biocartis Group NV's Receivables Turnover for the
six
months ended in Jun. 2023 was 1.55.
Biocartis Group NV (LTS:0R72) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Biocartis Group NV Receivables Turnover Related Terms
Biocartis Group NV Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Biocartis Group NV's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R72 vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Biocartis Group NV's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocartis Group NV Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biocartis Group NV's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Biocartis Group NV's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocartis Group NV (LTS:0R72) has a Receivables Turnover of 1.55 as of Jun. 2023. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Biocartis Group NV and its competitors.
Is Biocartis Group NV's Receivables Turnover too high?
Biocartis Group NV's current Receivables Turnover is 1.55. The Medical Diagnostics & Research industry median Receivables Turnover is 5.37. Biocartis Group NV's value of 1.55 is 71.1% below this industry median. Overall, Biocartis Group NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Biocartis Group NV's Receivables Turnover compare to TMO and DHR?
Biocartis Group NV's Receivables Turnover of 1.55 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Receivables Turnover is 5.37. Biocartis Group NV's value of 1.55 is 71.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.37, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocartis Group NV's current Receivables Turnover of 1.55 is 71.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Biocartis Group NV and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocartis Group NV's current Receivables Turnover is 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocartis Group NV stock overvalued right now?
Biocartis Group NV (LTS:0R72) has a current Receivables Turnover of 1.55. The current Receivables Turnover is 1.55 and 71.1% below the Medical Diagnostics & Research industry median of 5.37. Biocartis Group NV's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Biocartis Group NV (LTS:0R72), the current Receivables Turnover is 1.55 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an Meet Idylla molecular diagnostic system for oncology and infectious disease segments.
14GF Score
Get the complete analysis for LTS:0R72
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R72 has been successfully added to your 
